Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...

The growing emphasis on advanced liver fibrosis treatments highlights a paradigm shift in addressing chronic liver diseases, prioritizing early intervention and improved patient outcomes. Innovations ...

New Delhi, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The global liver fibrosis treatment market was valued at USD 17.51 billion in 2024 and is projected to reach USD 51.16 billion by 2033, growing at a ...

(MENAFN- GlobeNewsWire - Nasdaq) The growing emphasis on advanced liver fibrosis treatments highlights a paradigm shift in addressing chronic liver diseases, prioritizing early intervention and ...

CHICAGO, NY, UNITED STATES, January 21, 2025 /EINPresswire / -- The global liver fibrosis treatment market is set to witness significant expansion over the coming decade, with revenues anticipated ...

This study means that clinicians should use the AASLD/IDSA simplified treatment recommendation for FIB-4 for staging liver fibrosis “and identify those with advanced hepatic fibrosis/cirrhosis ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Right now, patients with obesity and cirrhosis have few treatments for their progressive liver disease, but a new study ...